Moody’s Investor Service said in a report this week that generic drug companies are facing increasing challenges about the prices they want to charge and regulatory oversight of the drugs they make and sell. The continued push by people…
Comment:*
Nickname*
E-mail*
Website
Save my name, email, and website in this browser for the next time I comment.
